Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Scienture Holdings (SCNX) Research & Development (2021 - 2025)

Scienture Holdings (SCNX) has disclosed Research & Development for 5 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 3.99% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 10.4% year-over-year, with the annual reading at $2.0 million for FY2025, 12.54% down from the prior year.
  • Research & Development hit $1.9 million in Q4 2025 for Scienture Holdings, up from $9756.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.9 million in Q4 2024 to a low of $9756.0 in Q3 2025.
  • Historically, Research & Development has averaged $340458.0 across 5 years, with a median of $186182.0 in 2021.
  • Biggest five-year swings in Research & Development: surged 7561.35% in 2024 and later tumbled 93.8% in 2025.
  • Year by year, Research & Development stood at $221595.0 in 2021, then skyrocketed by 36.42% to $302310.0 in 2022, then tumbled by 91.62% to $25334.0 in 2023, then soared by 7561.35% to $1.9 million in 2024, then dropped by 3.99% to $1.9 million in 2025.
  • Business Quant data shows Research & Development for SCNX at $1.9 million in Q4 2025, $9756.0 in Q3 2025, and $21408.0 in Q2 2025.